Interventional Cardiologists in the U.S. present a case series on the contemporary use of glycoprotein IIb/IIIa inhibitors (GPIs).
The series is based on cases where patient treatment included Aggrastat (tirofiban hydrochloride) injection and is intended to be an educational resource for fellows and those who may not be familiar with the use of GPIs.
These cases and testimonials are based on the experiences of a few people. Not all cases are identical. You are not likely to have similar results.
Important Safety Information about the use of Aggrastat is provided below.
Clinical studies performance with Aggrastat are provided in the full Prescribing Information.
We reached out to Interventional Cardiologists in the U.S. who had experience using Aggrastat and asked them to presented 3 cases in which they have used Aggrastat in their practice. All presenters were provided financial support for the creation of these videos by Medicure Inc. All cases presented are real cases.
Click the image below to see the 3 unique cases presented by each of the physician presenters, or scroll down to view all our entire case series.
Below you will find all cases that are currently available to view.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
or call 1-800-FDA-1088.